Clinical Implementation of Chromosomal Microarray Analysis within the Framework of Insurance Covered Medical Care

Abstract

Chromosomal microarray analysis (CMA) is a comprehensive genetic test within Japan’s insurance-covered medical care, offering genome-wide coverage and high resolution for identifying genetic causes of congenital anomalies and developmental delay. Its clinical implementation requires an organized workflow—ranging from institutional accreditation and pre-test counseling to report interpretation, result disclosure, and follow-up—and relies on multidisciplinary collaboration, including clinical geneticists. A central component in CMA-based practice is the evaluation of detected copy number variants (CNVs), involving guideline-based pathogenicity classification, cytogenetic inference of underlying mechanisms, and clinical interpretation to achieve an integrated diagnosis. Regions of homozygosity (ROH), though less common, may also be detected; when their inferred mechanisms suggest disease relevance, targeted follow-up testing can support diagnosis. Because CNV and ROH evaluation and clinical interpretation is the responsibility of ordering clinicians, professional societies continue to provide hands-on training. Finally, proactive and comprehensive clinical management remains crucial for translating genomic findings into meaningful outcomes for patients and families.